Stephen Saad (53)
Executive director; Aspen Group Chief Executive
Qualifications: CA(SA), Honorary doctorate
Appointed: January 1999
Stephen is a founding shareholder of the Aspen Group and his responsibilities extend to include the strategic positioning and global transactions, geographic expansion and product diversification of Aspen in developed and emerging markets as a leading multinational pharmaceutical company.
Gus Attridge (56)
Executive director; Deputy Group Chief Executive
Appointed: January 1999
A founder of Aspen, Gus is the Deputy Group Chief Executive of the Aspen Group. He is also a member of the Social & Ethics Committee and attends meetings of all of the other Board Committees by invitation. In addition to his other responsibilities, Gus also performs the duties of the Company’s Financial Director.
Kuseni Dlamini (49)
Independent non-executive, Chairman
Qualifications: MPhil (Oxon), BSocSci (Hons) (Natal), Global Leadership for the 21st Century Programme (Harvard), Foundations for Leadership in the 21st Century (Yale)
Appointed: April 2012
Kuseni is the Chairman of Massmart Holdings Limited. He was previously Chairman of Times Media Group Limited and Chief Executive Officer of Old Mutual South Africa and Emerging Markets. He brings a wealth of economic and business skills to the Board having previously held positions as the Head of Anglo American South Africa and Executive Chairman of Richards Bay Coal Terminal Company. Kuseni is the former Chairman of the South African National Parks (“SANParks”) and a former member of the Global Agenda Council on Economic Growth and Poverty Alleviation formed by the World Economic Forum. He is active in academic and professional bodies, which include the Council of the University of Pretoria, South African Institute of International Affairs (“SAIIA”), and the advisory boards of the Gordon Institute of Business Science and Common Purpose. Kuseni is a member of the Remuneration & Nomination Committee.
Roy Andersen (69)
Lead independent non-executive
Qualifications: CA(SA), CPA (Texas), CD (SA)
Appointed: August 2008
A Chartered Accountant by profession and with significant experience in the banking, insurance, construction and packaging industries, Roy’s expertise in fields such as governance and remuneration have been of great benefit to Aspen. He was previously Chairman and Chief Executive of Ernst & Young, Chief Executive of the Liberty Group Limited and a former President of JSE Limited. Roy is currently a non-executive director of Nampak Limited, chairman of SASFIN Holdings Limited and SASFIN Bank Limited and a major general in the South African National Defence Force, holding the post of Chief of Defence Reserves. He is a member of the King Committee on Corporate Governance. Roy serves as lead independent non-executive director and is the Chairman of the Remuneration & Nomination Committee and a member of the Audit & Risk Committee.
Linda de Beer (49)
Qualifications: CA(SA), MCom (Tax), Chartered Director
Appointed: July 2018
Linda serves as an independent non-executive director on a number of JSE-listed boards including Sasfin Holdings Limited, Royal Bafokeng Platinum Limited and Omnia Limited. She is the chairman of the audit committees of these boards and also serves on a number of their other sub-committees. In addition, she advises and trains boards, executives and prospective JSE sponsors on financial reporting, auditing and corporate governance. She is a member of the Investor Advisory Group of the Public Company Accounting Oversight Board (PCAOB) in the United States of America, a member of the King Committee, she chairs the Financial Reporting Investigation Panel of the JSE and is an Honorary Professor, on a part time basis, at the University of Johannesburg. Linda is also a member of the Audit & Risk Committee.
Chris Mortimer (56)
Qualifications: BA, LLB
Appointed: January 1999
Chris has been a full-time practising attorney since 1988 and has substantial legal and commercial expertise. His intimate knowledge of the Group, its business operations and governance processes have been of immense benefit to Aspen over the years and he continues to serve the Board as a trusted adviser. As Chris’s firm is intermittently called upon to provide legal advice to the Group, he is classified as a non-independent non-executive director.
Babalwa Ngonyama (43)
Qualifications: CA(SA), MBA, Higher Diploma in Banking Law (RAU)
Appointed: April 2016
Babalwa is the CEO of Sinayo Securities (Pty) Limited, a women-owned and managed securities firm, and the Deputy Chairperson of Brand South Africa. Prior to this, she held positions as the Group Chief Internal Auditor of Nedbank Limited, Chief Financial Officer of Safika Holdings (Pty) Limited, partner at Deloitte (Financial Institutions Services Team and Chairperson of the Transformation Advisory Board), and audit partner at Nkonki Incorporated. She is, among others, a non-executive director and member of the audit committees of Impala Platinum Holdings Limited, and formerly of Barloworld Limited, and therefore brings considerable financial and commercial experience to the Board. In August 2008, she received an award as a BBQ business woman visionary. Babalwa was a member of the Education and Academic Review Committees of the South African Institute of Chartered Accountants (“SAICA”), she was the founding Chairman of the African Women Chartered Accountants (“AWCA”), and currently a member of its Advisory Board. Babalwa is a member of the Audit & Risk Committee.
David Redfern (51)
Qualifications: BSc (Hons), CA
Appointed: February 2015
David was appointed chief strategy officer of GSK in May 2008 and is responsible for corporate development and strategic planning. He has, in this role, assisted GSK in numerous bolt-on acquisitions and joint ventures including, in particular, a multi-billion dollar three-way asset swap with Novartis. He is a member of GSK’s Corporate Executive Team and reports to the CEO. Prior to holding this position, he was responsible for the leadership of GSK’s business in Northern Europe from 2005 to 2008 and Central and Eastern Europe from 2002 to 2005. He joined Glaxo in 1994 in finance and progressed through a series of finance roles before becoming Finance Director of the European business in 1999. In addition to his current role, David is Chairman of ViiV Healthcare Limited. ViiV is a joint venture between GSK, Pfizer and Shionogi and focuses specifically on the development and commercialisation of medicines to treat HIV.
Sindi Zilwa (50)
Qualifications: CA(SA), CD(SA), Advanced Taxation Certificate (UNISA), Advanced Diploma in Financial Planning (UOFS) and Advanced Diploma in Banking (RAU)
Appointed: September 2006
Sindi is the co-founder and retired chief executive officer of Nkonki Incorporated, having held the position from 1998 to 2016. A Chartered Accountant by profession, Sindi is an expert in the areas of accounting, auditing and business management. Sindi is also a Chartered Director (SA) and has vast experience as a director in the public and private sectors, currently serving as a non-executive director of Discovery Holdings Limited, AngloGold Ashanti Limited, Metrofile Limited and Gijima Limited, among others. She is an author of “The ACE Model-Winning Formula for Audit Committees”, used by the Institute of Directors to train audit committee members in South Africa, and the author of “Creating Board and Committee Effectiveness”. She is a member of the South African Institute of Chartered Accountants and Independent Regulatory Board for Auditors. Sindi was previously non-executive Chairman of Airports Company South Africa and a non-executive director of Woolworths Limited, Primedia Limited, Wiphold Limited, Ethos Private Equity, Institute of Directors, Alexkor Limited, Rebosis Limited, ATNS SOC Limited and previously chaired the BUSA Standing Committee on Transformation. Sindi serves as Chairman of the Social & Ethics Committee and is a member of the Audit & Risk Committee.